# Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer

> **NCT00521404** · PHASE2 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 65 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** CS-1008 (humanized anti-DR5 antibody)
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT00521404
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08-15
- **Primary completion:** 2010-08-20
- **Final completion:** 2010-08-20
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00521404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00521404, "Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00521404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*